Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study

carcinoma. Urol Clin North Am 2010; 37: 467–474. 136. Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65: 433–438. 137. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147: 630–632. 138. Di Lorenzo G, Buonerba C, Federico P et al. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int 2012 September 10 [epub ahead of print]. 139. Necchi A, Nicolai N, Piva L et al. A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of the penis: a single institution series. Ann Oncol 2010; 21(Suppl 8): viii271–viii303, abstr 939P. 140. Theodore C, Skoneczna I, Bodrogi I et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19: 1304–1307. 141. Power DG, Galvin DJ, Cuffe S et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol 2009; 27: 187–190. 142. Di Lorenzo G, Federico P, Buonerba C et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60: 1280–1284. 143. Carthon BC, Pettaway C, Pagliaro LC. Epidermal growth factor receptor (EGFR) targeted therapy in advanced metastatic squamous cell carcinoma (AMSCC) of the penis: updates and molecular analyses. J Clin Oncol 2010; 28 (Suppl); abstr e15022. 144. Necchi A, Nicolai N, Colecchia M et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011; 29: e650–e652. 145. Rescigno P, Matano E, Raimondo L et al. Combination of docetaxel and cetuximab for penile cancer: a case report and literature review. Anticancer Drugs 2012; 23: 573–577. 146. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107–1113. 147. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996. 148. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–697. 149. Lucky MA, Rogers B, Parr NJ. Referrals into a dedicated British penile cancer centre and sources of possible delay. Sex Transm Infect 2009; 85: 527–530. 150. Ivy SP, Siu LL, Garrett-Mayer E et al. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010; 16: 1726–1736.